## Supplemental figure 1



Flow cytometry analysis of TREM-1 expression on circulating monocytes after 3 days of AngII infusion in *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* and *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* mice.



AAA incidence at day 28 after AngII infusion in *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* (left) and *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* mice (right).



Survival curve of Angll-infused Apoe<sup>-/-</sup>Trem1<sup>+/+</sup> (pink) and Apoe<sup>-/-</sup>Trem1<sup>-/-</sup> mice (black) (N=18-20/group)



Systolic blood pressure of *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* (pink) and *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* mice (black) at baseline and after AngII infusion (1µg/kg/min) (N=5-7/group). \*P<0.05



Quantification of *Eln* mRNA expression in aorta at day 7 after AngII infusion, by RT-qPCR (N=9 in *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* group, N=6 in *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* group).



CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophil count in aorta of *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* (pink) and *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* mice (black) at day 3 after AngII infusion (1000 ng/kg/min) (N=5/group).



CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>hi</sup> monocyte count in the spleen of *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* (pink) and *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* mice (black) at day 3 after AnglI infusion (1000 ng/kg/min) (N=8 in *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* group, N=7 in *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* group).





Flow cytometry quantification of TREM-1 expression on Ly6C<sup>hi</sup> classical monocytes of Isotype-treated (clear blue square) and TREM-1 Ab-treated (solid blue square) *Apoe<sup>-/-</sup>*mice, 3 days after AngII infusion (1000 ng/kg/min) (N=13 in Isotype Ab group, N=10 in TREM-1 Ab group). \*\*\*P<0.001.



Systolic blood pressure of Isotype-treated (clear blue square) and TREM-1 Ab-treated (solid blue square) Apoe<sup>-/-</sup> mice, 15 days after AngII infusion (1000 ng/kg/min) (N=7 in Isotype Ab group, N=8 in TREM-1 Ab group), \*\*\*P<0.001.



Flow cytometry quantification of CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils and CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>low</sup> non classical monocytes into the aortic wall at day 3 after AngII infusion (1000 ng/kg/min) (N=13 in Isotype Ab group, N=10 in TREM-1 Ab group).



Quantification of CD62L expression (MFI) on circulating Ly6C<sup>hi</sup> classical monocytes by flow cytometry 1 day after AngII infusion (1000 ng/kg/min) (N=5 in *Apoe<sup>-/-</sup>Trem1<sup>+/+</sup>* group, N=4 in *Apoe<sup>-/-</sup>Trem1<sup>-/-</sup>* group), \*P<0.05.



Correlation between TREM-1 and CD62L expression on circulating Ly6C<sup>hi</sup> classical monocytes quantified by flow cytometry 3 days after AnglI infusion (1000 ng/kg/min), \*\*P<0.01.



Flow cytometry analysis of CD62L neutralization on Ly6C<sup>hi</sup> classical monocytes. *Apoe<sup>-/-</sup>* mice were implanted with subcutaneous osmotic minipumps infusing AngII (1000 ng/kg/min) and were treated with either an anti-TREM-1 agonistic antibody (TREM-1 Ab) or an isotype control (Isotype Ab) every day during 3 days. In addition, animals received neutralizing anti-CD62L antibody IV (100µg/mice/d) at day 0 and Day 1.



Flow cytometry analysis of TREM-1 expression on circulating CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils at baseline and 3 days after PBS or AngII infusion (1000 ng/kg/min) in *Apoe<sup>-/-</sup>* mice (N=4-5/group).



Flow cytometry analysis of TREM-1 expression on circulating CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>low</sup> non-classical monocytes at baseline and 3 days after PBS or AnglI infusion (1000 ng/kg/min) in *Apoe<sup>-/-</sup>* mice (N=5-6/group).

TREM-1+ Neutrophils (Blood)



Flow cytometry analysis of TREM-1 expression on circulating and splenic CD11b<sup>+</sup> Ly6G<sup>+</sup> neutrophils at baseline and day 3 day after AnglI (1000 ng/kg/min) or PBS infusion (N=5/group).



Flow cytometry analysis of TREM-1 expression on CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>lo</sup> non-classical monocytes at baseline and after PBS or AngII infusion (1000 ng/kg/min) in the blood of C57BL/6J mice (N=5/group).

## Supplemental figure 18



Flow cytometry analysis of TREM-1 expression on CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>high</sup> classical monocytes at baseline and at day 3 day after PBS or AngII infusion (1000 ng/kg/min) in the spleen of C57BL/6J mice.



Systolic Blood Pressure and quantification of TREM-1 expression on circulating Ly6C<sup>hi</sup> classical monocytes by flow cytometry 3 day after PBS or Norepinephrine (NE) infusion (5.6 mg/kg/j) (N=4-5/group). \*P<0.05.



SELL mRNA expression was quantified in normal aorta (from organ donors) and in AAA (neck and body) by RTqPCR. SELL mRNA expression was significantly higher in AAA tissues than in normal aorta tissue.\*P<0.05